Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04056962|
Recruitment Status : Recruiting
First Posted : August 14, 2019
Last Update Posted : October 3, 2019
|Condition or disease||Intervention/treatment||Phase|
|Tacrolimus, Kaposiform Hemangioendothelioma, Tufted Angioma||Drug: Tacrolimus ointment||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study|
|Actual Study Start Date :||September 1, 2019|
|Estimated Primary Completion Date :||August 30, 2021|
|Estimated Study Completion Date :||February 28, 2022|
|Experimental: patients treated with Tacrolimus ointment||
Drug: Tacrolimus ointment
topical application of tacrolimus for treatment of superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
- reduction in the size of the lesion [ Time Frame: 2.5 years ]Therapeutic effect is evaluated by reduction in the size of the tumor measured by centimeters.
- Rate of Adverse events [ Time Frame: 2.5 years ]using the measurement of ratio to evaluate the rate of adverse events of topical application of tacrolimus (such as ratio of Acne vulgaris, pruritis and rash etc.).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04056962
|Contact: Yi Ji, PHD, MD||+86 firstname.lastname@example.org|
|West China Hospital of Sichuan University||Recruiting|
|Chengdu, Sichuan, China, 610041|
|Contact: Yi Ji, MD 86 18980606865 email@example.com|
|Principal Investigator:||Yi Ji||West China Hospital|